The involvement of protein kinase C isoenzymes α, ε and ζ in the sensitivity to antitumor treatment and apoptosis induction

Anticancer Research

Volumn 19, Issue 5 B, 1999, Pages 3969-3976

  Spitaler, Martin ^a   Wiesenhofer, Bettina ^a   Biedermann, Verena ^a   Seppi, Thomas ^a   Zimmermann, Juerg ^b   Grunicke, Hans ^a   Hofmann, Johann ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Anticancer drugs; Apoptosis; Drug resistance; Isoenzymes; Protein kinase C

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CGP 53506; CISPLATIN; DOXORUBICIN; ISOENZYME; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; PROTEIN P53; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL PROLIFERATION; CELL STRAIN 3T3; CONTROLLED STUDY; DRUG SENSITIVITY; GAMMA IRRADIATION; GLIOBLASTOMA; HELA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

3T3 CELLS; ANIMALS; ANNEXIN A5; APOPTOSIS; BLOTTING, WESTERN; CELL DIVISION; CISPLATIN; DOWN-REGULATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GAMMA RAYS; HELA CELLS; HUMANS; ISOENZYMES; MICE; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN KINASE C; PROTEIN KINASE C-ALPHA; PROTEIN KINASE C-EPSILON; PYRIMIDINES; TIME FACTORS;

EID: 0032787540     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Goldie JH and Coldman AJ: The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res 4: 3643-3653, 1984.
2. Basu A: The potential of protein kinase C as a target for anticancer treatment. Pharmacol Ther 59: 257-280 1993
3. Hofmann J, Doppler W, Jakob A, Maly K, Posch L, Überall F and Grunicke H: Enhancement of the antiproliferative effect of cis-diamminedichloroplatinum(II) and nitrogen mustard by inhibitors of protein kinase. C Int J Cancer 42: 382-388, 1988.
4. Hofmann J, Überall F, Posch L, Maly K, Herrmann DBJ, and Grunicke H: Synergistic enhancement of the antiproliferative activity of cis-diamminedichloroplatinum(II) by the new ether lipid analogue BM 41 440, an inhibitor of protein kinase C. Lipids 24: 312-317, 1989.
5. Hofmann J, Fiebig HH, Winterhalter BR, Berger DP and Grunicke H: Enhancement of the antiproliferative activity of cis-diamminedichloroplatinum(II) by quercetin. Int J Cancer 45: 536-539, 1990.
6. Noseda A, Berens ME, White JG and Modest EJ: In vitro antiproliferative activity of combinations of ether lipid analogues and DNA interactive agents against human tumor cells. Cancer Res 48: 1788-1791, 1988.
7. Isonishi S, Andrews PA and Howell SB: Increased sensitivity to cis diamminedichloroplatinum(II) in human ovarian carcinoma cells in response to treatment with 12-O-tetradecanoylphorbol-13-acetate. J Biol Chem 265: 3623-3627, 1990.
8. Lucas M and Sanchez-Margalet V: Protein kinase C involvement in apoptosis. Gen Pharmacol 26: 881-887, 1996.
9. Lavin MF, Watters D and Song Q: Role of protein kinase activity in apoptosis. Experientia 52: 979-994, 1996.
10. Grant S and Jarvis DW: Modulation of drug-induced apoptosis by interruption of protein kinase C signal transduction pathway: a new therapeutic strategy. Clin Cancer Res 2: 1915-1920, 1996.
11. Jarvis WD, Turner AJ, Povirk LF, Traylor RS and Grant, S: Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors ot protein kinase C. Cancer Res 54: 1707-1714, 1994.
12. Jarvis WD, Povirk LF, Turner AJ, Traylor RS, Gewirtz DA, Pettit GR and Grant, S: Effects of bryostatin 1 and other pharmacological activators of protein kinase C on 1 [beta D arabinofuranosyl] cytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells. Biochem Pharmacol 47: 839-852, 1994.
13. Grant S, Turner A, Bartimole TM, Nelms P, Joe VC and Jarvis WD: Modulation of 1-β-D-arabinofuranosylcytosine-induced apoptosis in human promyelocytic leukemia cells by staurosporine and other inhibitors of protein kinase C. Oncol Res 6: 87-99, 1994.
14. Schwartz GK, Haimovitz-Friedman A, Dhupar SK, Ehleiter D, Maslak P, Lai L, Loganzo FJr, Kelsen DP, Fuks Z and Albino AP: Potentiation of apoptosis by treatment with the protein kinase C-specific inhibitor safingol in mitomycin C-treated gastric cancer cells. J Natl Cancer Inst 87: 1394-1399, 1995.
15. Kharbanda S, Datta R and Kufe D: Regulation of c jun gene expression in HL-60 leukemia cells by 1-beta-D-arabinofuranosylcytosine: Potential involvement of a protein kinase C-dependent mechanism. Biochemistry 30: 7947-7952, 1991.
16. Mailhos C, Howard MK and Latchman DS: A common pathway mediates retinoic acid and PMA-dependent programmed cell death (apoptosis) of neuronal cells. Brain Res 644: 7-12, 1994.
17. Leszczynski D, Joenvaara S and Foegh ML: Protein kinase C alpha regulates proliferation but not apoptosis in rat coronary vascular smooth muscle cells. Life Sci 58: 599-606, 1996.
18. Powell CT, Brittis NJ, Stec D, Hug H, Heston WD and Fair WR: Persistent membrane translocation of protein kinase C alpha during 12-0-tetradecanoylphorbol-13-acetate-induced apoptosis of LNCaP human prostate cancer cells. Cell Growth Differ 7: 419-428, 1996.
19. Chakrabarty S and Huang S: Modulation of chemosensitivity in human colon carcinoma cells by downregulating protein kinase C alpha expression. J Exp Ther Oncol 1: 218-221, 1996.
20. Whelan RD and Parker PJ: Loss of protein kinase C function induces an apoptotic response. Oncogene 16: 1939-1944, 1998.
21. Iwata M, Iseki R, Sato K, Tozawa Y and Ohoka Y: Involvement of protein kinase C epsilon in glucocorticoid-induced apoptosis in thymocytes. Int Immunol 6: 431-438, 1994
22. Basu A and Cline JS: Oncogenic transformation alters cisplatin-induced apoptosis in rat embryo fibroblasts. Int J Cancer 63: 597-603, 1995.
23. Gray MO, Karliner JS and Mochly-Rosen D: A selective epsilon-protein kinase C antagonist inhibits protection of cardiac myocytes from hypoxia-induced cell death. J Biol Chem 272: 30945-30951, 1997.
24. Hannun YA: Functions of ceramide in coordinating cellular responses to stress. Science 274: 1855-1859, 1998.
25. Lozano J, Berra E, Municio MM, Diaz-Meco MT, Dominguez I, Sanz L and Moscat J: Protein kinase C zeta isoform is critical for kappa B-dependent promoter activation by sphingomyelinase. J Biol Chem 269: 19200-19002, 1994.
26. Berra E, Municio MM, Sanz L, Frutos S, Diaz-Meco MT and Moscat J: Positioning atypical protein kinase C isoforms in the UV-induced apoptotic signaling cascade. Mol Cell Biol 17: 4346-4354, 1997.
27. Diaz-Meco MT, Municio MM, Frutos S, Sanchez P, Lozano J, Sanz L and Moscat J: The product of par-4, a gene induced during apoptosis, interacts selectively with the atypical isoforms of protein kinase C. Cell 86: 777-786, 1996.
28. Goodnight J, Mischak H, Kolch W and Muschinski JF: Immunocytochemical localization of eight protein kinase C isoenzymes overexpressed in NIH3T3 fibroblasts. J Biol Chem 268: 9991-10001, 1995.
29. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren, JT, Bokesch H, Kenney S and Boyd MR: New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112, 1990.
30. Blobe GC, Obeid LM and Hannun YA: Regulation of protein kinase C and role in cancer biology. Cancer Metastasis Rev 13: 411-431, 1994.
31. Zimmermann J, Caravatti G, Mett H, Meyer T, Müller M, Lydon NB and Fabbro D: Phenylamino-pyrimidine (PAP) derivates a new class of potent and selective inhibitors of protein kinase C (PKC). Arch Pharm Pharm Med Chem 329: 371-376, 1996.
32. Dean N, McKay R, Miraglia L, Howard R, Cooper S, Giddings J, Nicklin P, Meister L, Ziel R, Geiger T, Muller M, and Fabbro D: Inhibition of growth of human tumor cell lines in nude mice by an antisense oligonucleotide inhibitor of protein kinase C-a expression. Cancer Res 56: 3499-3507, 1996.
33. Yazaki T, Ahmad S, Chahlavi A, Zylber-Katz E, Dean NM, Rabkin SD, Martuza RL and Glazer RI: Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide. Mol Pharmacol 50: 236-242, 1996.
34. Leszczynski D, Joenvaara S and Foegh ML: Apoptosis of rat vascular smooth muscle cells is regulated by δ and ζ but not by α and ε isozymes of protein kinase C. Mol Biol Cell 6: Suppl, 246a, 1995.
35. Geiger T, Muller M, Dean NM and Fabbro D: Antitumor activity of a PKC-alpha antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice. Anticancer Drug Des 13: 35-45, 1998.
36. Adams LM, Dykes D, Harrison SD, Saleh J and Saah L: Combined effect of the chemopotentiator SPC-100270, a protein kinase C (PKC) inhibitor, and doxorubicin (dox) or cisplatin (cis) on murine isografts and human tumor xenografts. Proc Am Assoc Cancer Res 34: 410, 2448, 1993.
37. Akinaga S, Nomura K, Gomi K and Okabe, M: Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C. Cancer Chemother Pharmacol 32: 183-189, 1993.
38. Czendlik C, and Graf P: Safety, tolerability and pharmacokinetics of CGP 41251, a protein kinase C inhibitor (phase I study). Ann Oncol 7: Suppl 1, 264, 1996.
39. Shen L and Glazer RI: Induction of apoptosis in glioblastoma cells by inhibition of protein kinase C and its association with the rapid accumulation of p53 and induction of the insulin-like growth factor-1-binding-protein-3. Biochem Pharmacol 55: 1711-1719, 1998.
40. Alvaro V, Levy L, Dubray C, Roche A, Peillon F, Querat B and Joubert D: Invasive human pituitary tumors express a point-mutated alpha-protein kinase C. J Clin Endocrinol Metab 77: 1125-1129, 1993.
41. Basu A and Weixel KM: Comparison of protein kinase C activity and isoform expression in cisplatin-sensitive and -resistant ovarian carcinoma cells Int J Cancer 62: 457-460, 1995.
42. Ohmori T and Arteaga CL: Protein kinase C epsilon translocation and phosphorylation by cis-diamminedichloroplatinum(II) (CDDP) potential role in CDDP-mediated cytotoxicity. Cell Growth Differ 9: 345-353, 1998.
43. Murray NR and Fields AP: Atypical protein kinase C L protects human leukemia cells against drug-induced apoptosis. J Biol Chem 272: 27521-27524, 1997.
44. Kolch W, Heidecker B, Kochs G, Hummel R, Vahidi M, Mischak H, Finkenzeller G, Marme D and Rapp UR: Protein kinase C alpha activates RAF-1 by direct phosphorylation. Nature 364: 249-252, 1993.
45. Ruvolo PP, Deng X, Carr BK, and May WS: A functional role for mitochondrial protein kinase C-alpha in Bcl2 phosphorylation and suppression of apoptosis. J Biol Chem 273: 25436-25442, 1998.
46. Blagosklonny MV, Giannakakou P, el-Deiry WS, Kingston DG, Higgs PI, Neckers L and Fojo T: Raf-1/bcl-2 phosphorylation a step from microtubule damage to cell death. Cancer Res 57: 130-135, 1997.